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Abstract: Neuromuscular junction assembly and plasticity during embryonic, postnatal, and adult
life are tightly regulated by the continuous cross-talk among motor nerve endings, muscle fibers,
and glial cells. Altered communications among these components is thought to be responsible for
the physiological age-related changes at this synapse and possibly for its destruction in pathological
states. Neuromuscular junction dismantling plays a crucial role in the onset of Amyotrophic Lateral
Sclerosis (ALS). ALS is characterized by the degeneration and death of motor neurons leading to
skeletal muscle denervation, atrophy and, most often, death of the patient within five years from
diagnosis. ALS is a non-cell autonomous disease as, besides motor neuron degeneration, glial cells,
and possibly muscle fibers, play a role in its onset and progression. Here, we will review the recent
literature regarding the mechanisms leading to neuromuscular junction disassembly and muscle
denervation focusing on the role of the three players of this peripheral tripartite synapse.
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1. The Neuromuscular Junction as a Tripartite Synapse
At the end of the 1990, it was proposed that glial cells, besides providing the ideal milieu for
neuronal function, might have a role in the modulation of neuronal activity, synaptic neurotransmission,
and plasticity. It was shown that they were able to respond to neuronal activity by increasing their
intracellular Ca2+ concentration [1] and releasing chemical gliotransmitters (i.e., glutamate, D-serine,
and adenosine triphosphate (ATP) from astrocytes) [1–3], thus modulating the activity of neurons
and the strength of their signaling. These considerations led to the definition of the tripartite synapse,
where not only the pre- and postsynaptic neurons, but also glial cells, were active partners. Even if
the concept of tripartite synapse was initially developed for glutamatergic synapses in the central
nervous system (CNS), early studies demonstrated that terminal Schwann cells (TSCs) (or perisynaptic
Schwann cells) were equally able to modulate acetylcholine release at the frog neuromuscular junction
(NMJ) [3] and, to date, the NMJ is considered a peripheral tripartite synapse that is formed by the
motor neuron nerve ending, the postsynaptic membrane on skeletal muscle fiber and the TSCs.
The role of these three cellular components in the physiology of the NMJ has been extensively
investigated; nonetheless, the contribution of TSCs and muscle fibers in NMJ disassembly in
pathological states is still a matter of debate. The scope of this review is to summarize the recent
literature describing the contribution of all the elements of the NMJ in the events leading to skeletal
muscle denervation in Amyotrophic Lateral Sclerosis (ALS). For a better understanding of these
pathological events it is necessary to recapitulate which are the main steps in the assembly and
maintenance of the NMJ as, as it is often the case, these might be altered in degenerative processes.
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2. Neuromuscular Junction Assembly and Plasticity
Cross-Talk during Neuromuscular Junction Assembly
Which is the first event in the formation of the NMJ has long been considered as a chicken-and-egg
problem [4]; which factors and pathways are initially involved in the formation of such synapse during
embryonic development (in rodents, between embryonic day 12 and 13.5)? Which of the cell types
involved is triggering the event? The first hypotheses about NMJ formation pointed to the prominent
role of motor neurons that contacted newly-formed acetylcholine receptor clusters on the muscle
plasma membrane (neurocentric hypothesis). According to this view, the clustering of the receptors
was induced by the release of agrin by the neuron itself through activation of the muscle specific kinase
(MuSK) on the muscle membrane. Subsequently it was shown (both in vitro and in vivo) [5–9] that
clusters of acetylcholine receptors (AChRs) could form even in the absence of incoming motor axons
and their signaling [6,9], leading to a different hypothesis (known as myocentric) of NMJ formation as a
muscle-initiated event. According to this hypothesis muscle derived cues define the area in which NMJ
can form on the muscle fiber. These cues are represented by the patterned and restricted expression,
on the muscle fiber plasma membrane, of MuSK and Lrp4 (low-density lipoprotein receptor-related
protein 4), the agrin co-receptor, and by the agrin-independent activation of MuSK [10] (Figure 1).
Importantly, muscle fibers are also responsible for the synthesis and secretion of the extracellular
matrix proteins (i.e., laminins) that will compose the synaptic basal lamina, a structure that, in time,
has been demonstrated to play a pivotal role in different aspects of NMJ development, such as synaptic
initiation, maturation, and stability, but also in maintaining its structural integrity [11].
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the fiber plasma membrane defines the area in which neuromuscular synapse will form, before the 
arrival of the incoming nerve ending (see text). 
Figure 1. Neurocentric and myocentric hypotheses of neuromuscular synaptogenesis. According to
the neurocentric hypothesis, the clustering of the acethylcholine receptors (AChRs) on the muscle fiber
plasma membrane is primarily triggered by the release of neural agrin and through activation of the
muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein (Lrp4). According
to the myocentric hypothesis, patterned and restricted expression of MuSK and Lrp4 on the fiber
plasma membrane defines the area in which neuromuscular synapse will form, before the arrival of the
incoming nerve ending (see text).
Both neuro- and myocentric hypothesis, however, did not take into account the role of Schwann
cells in NMJ formation. Even if it is now acknowledged that Schwann cells are not necessary for the
establishment of the first contact between nerve and muscle [12], recent studies on the development
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of the NMJ in different animal models have revealed that these cells release factors (i.e., agrin, WNT
ligands, neuregulin 1, Glial cell-derived neurotrophic factor (GDNF), and Transforming growth factor
(TGF)β) that can influence NMJ assembly and pre- and postsynaptic maturation and, on their turn,
TSCs maturation is modulated by pre- and postsynaptically released factors (neuregulin 1, ATP, and
laminins) [13].
As it occurs in central synapses, NMJs undergo a long maturation process where the pre- and
postsynaptic apparatus are shaped by synaptic activity, whereas the number and size of TSCs change.
Finally nerve terminals compete with each other to innervate each muscle fiber and, eventually, in the
early postnatal period, this competition will evolve into the elimination of supernumerary inputs. The
result of these processes is a scenario in which a single nerve terminal innervates a well-organized
postsynaptic specialization in each fiber. Recent studies based on Schwann cell ablation during
embryonic and early postnatal life in mice, suggest that during these later phases of NMJ development,
TSCs specifically modulate AChRs maturation, and that they are equally important for NMJ stability
in adult life [14].
Most of the molecules that play crucial roles in NMJ formation are also essential for its maintenance
in adult life where NMJ integrity tightly depends on the presynaptic release of acetylcholine and on
the clustering of AChRs on the muscle plasma membrane to trigger muscle action potentials. Loss of
function mutations in human genes coding for AChRs subunits, Nav1.4 (the sodium channel isoform
that is enriched in the postsynaptic cleft’s secondary folds and is essential for the initiation of the
muscle action potential), Rapsyn (the AChRs clustering molecule at the postsynaptic membrane), and
ColQ (the collagen tail of acetylcholinesterase, the enzyme responsible for the termination of signal
transduction in NMJ), all result in the NMJ impairments that are at the basis of most cases of Congenital
Myastenic Syndrome (CMS). In addition to these molecular components of the neurotransmission
machinery, mutations in genes coding for agrin, Lrp4, MuSK, Dok-7 (a muscle-intrinsic activator of
MuSK), and Laminin β2 have also been shown to be associated with CMS [15]. Inducible and/or
conditional suppression of the expression of agrin, Lrp4, MuSK, and Laminin β2 in postnatal mice and
rats has shown that these molecules are required to maintain adult NMJs [16]. Mature presynaptic
elements of the NMJ need the continuous support of the TSCs to be maintained and to finely tune
neurotransmission. This has been shown in the adult frog NMJ where, one week after TSCs ablation, a
certain degree of retraction of nerve endings, as well as a significant reduction in neurotransmitter
release is observed [12].
3. The Neuromuscular Junction in Aging
Aging is characterized by a progressive reduction in muscle mass and strength and by a reduced
ability of the fibers to regenerate upon injury [16,17]. Similarly, aging is associated with a reduction
in the number of motor neurons in the spinal cord [18]. The loss of motor neurons results in the
denervation of entire motor units that become re-innervated by the expansion of other pre-existing
motor units. The sprouting of new branches from surviving motor axons leads to functional
reinnervation of previously-denervated muscle fibers. However, when denervation exceeds the
compensatory reinnervation capabilities of aging muscles, denervated muscle fibers are eliminated
and the progressive decline in mass and strength become apparent.
While being considered highly stable synapses during a vertebrate life, neuromuscular junctions
undergo profound morphological and functional changes in aging. Among the structural alterations
of the NMJ that are more frequently observed in aged muscles there is: (1) the increased surface of
the postsynaptic area with the degeneration of a subset of junction folds and the fragmentation of the
clusters of AChRs together with the insertion or migration of extrasynaptic AChRs in the perijunctional
area [16,19]; (2) several AChR clusters are devoid of presynaptic inputs or, more frequently, these are
not covering the entire surface of the clusters, leading to a partial focal denervation; (3) some nerve
endings are thinner, while others are swollen, compared to those observed in younger muscle NMJs
and, occasionally, two nerve endings innervate a single postsynaptic receptor cluster in a configuration
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the is reminiscent of the poly-neuronal innervation of immature developing NMJ [19]. This failure in
the proper re-establishment of the single neuronal innervation might depend on the impairment in
the growth of regenerating nerve endings and on the less precise apposition of pre- and postsynaptic
specializations that are due to the reduced capability of TSCs to efficiently and precisely re-occupy
synaptic sites following denervation. Indeed, in NMJs from aged patients TSC processes were seen to
invade the primary synaptic cleft [16].
Reduced levels of the active zone protein Bassoon were detected in presynaptic terminals of aged
NMJs, suggesting impairments in active zone formation and synaptic transmission. These data were
consistent with the defects in synaptic functions that have been reported in time, namely reduced
end-plate potential and stronger synaptic depression after repeated stimulation and reduced frequency
of miniature end-plate potentials [20].
To date it is not known whether changes of NMJs in aging muscle are primarily caused by the
changes occurring to the motor neuron or to the muscle fiber.
In the past few years, it has been shown that the same factors that are involved in the formation of
the NMJ are also needed for its maintenance in adulthood and that altered levels of expression of these
factors correlate with the physiological aging of this synapse. Recent data showed that genes coding
for different subunits of the AChR (α, δ, γ), as well as MuSK and Lrp4, were significantly up-regulated
in aged rats [21,22]. Interestingly these same genes were upregulated upon denervation, thus, these
data established a causal link between age-induced sarcopenia and denervation on one hand, while, on
the other hand, they suggested that the agrin-MuSK signaling pathway is also involved in age-related
changes at the NMJ. Further evidence about the involvement of the Agrin/MuSK/Lrp4 pathway in
age-related changes at the NMJ and the reduction in muscle mass come from the observation that, by
overexpressing neurotrypsin, the neural serin-protease that is responsible for the inactivating cleavage
of agrin, not only are NMJs dismantled in a few days, but a full sarcopenic phenotype is achieved in
young adult mice [23].
Cholinergic neurotransmission defects at the NMJ occur with aging but their role in age-related
changes at this synapse has long been poorly understood. What is now known is that, by slightly
increasing the amount of acetylcholine in the synaptic cleft, adult mice NMJs start to degenerate,
suggesting that maintaining normal cholinergic signaling is crucial to slow age-related changes at the
NMJ [24].
The extended ACh lifetime in the NMJ cleft led to prolonged currents and potentials. At the same
time there is a significant reduction in the amount of available neurotransmitter within the synaptic
vesicle due to the impairment in cholinesterase activity [15].
During the period of relative stability of the mature NMJ, all trophic factors and signals deriving
from the three partners of the synapse are tightly tuned to maintain an equilibrium that is regulated by
synaptic activity and acetylcholine. In aging NMJs this equilibrium is disrupted and, in this context,
the circulating levels of neurotrophic and growth factors might be relevant. Indeed, the age-related
reduction in the levels of both brain-derived neurotrophic factor (BDNF) and GDNF might play a role
in changes of the NMJ in aging [17]. Muscle fibers synthesis and secretion of fibroblast growth factor
binding protein 1 (FGFBP1) is restricted to the NMJ area. While the expression of FGFBP1 increases
during NMJ development, it decreases in aging fibers and its decrease precedes NMJ alterations in
aging. The deletion of FGFBP1 in mice results in defects in NMJ formation and stability [25]. The level
of the circulating isoform of insulin-like growth factor 1 (IGF-1) declines with age and this reduction
may contribute to NMJ degeneration and muscle fiber denervation. Indeed it was shown that in old
mice overexpressing IGF-1 in muscles, the sarcopenic phenotype was abolished and the integrity of
NMJ innervation was maintained, and similar results were obtained with the systemic administration
of IGF-1 in experimental models of denervation [17]. Another factor that causes a reduction in the level
and efficacy of circulating IGF-1 is inflammation and it is known that aging is accompanied by a chronic
mild inflammatory state sustained by increased levels of inflammatory cytokines, like interleukin 6
(IL-6), interleukin 1 (IL-1), tumor necrosis factor α (TNFα), and C-reactive protein (CRP) [17].
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Mitochondrial dysfunction has long been known to be involved in age-related alteration of the
motor system; studies on post-mortem spinal cord samples from the elderly indicated that up to 35%
of the motor neurons’ soma contained mitochondria that were lacking in elements of the respiratory
chain complexes [26]. However, only recently a systematic study addressed the role of mitochondria
in the aging NMJ. Ultrastructural analyses of motor neurons from old rats revealed that in the nerve
endings mitochondria presented a number of abnormalities (i.e., swelling and increased size, possibly
due to an imbalance in fusion/fission dynamics) that were not observed in the motor neuron soma.
Moreover in the cytoplasm of the axon terminals activated caspase 3 and cytochrome C (triggers of the
mitochondrial-dependent pathway to apoptosis) were detected, pointing to the nerve ending as the
primary site of motor neuron degeneration in aging [27].
The number of mitochondria in skeletal muscle that decrease with age, possibly due to a reduced
mitochondrial biogenesis. However, it is still a matter of debate whether this reduction is due to
decreased levels of the peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α) (known
as a master regulator of mitochondrial biogenesis) in aging muscles [26].
Several of the events and pathways that are involved in the physiological aging of NMJs and
muscles are equally involved in the NMJ defects and skeletal muscle denervation that occur in
Amyotrophic Lateral Sclerosis (ALS). Elderly people and ALS patients share common features, starting
from reduction in muscle mass and strength, altered metabolism of muscle fibers, which correlates not
only with aging, but also with reduced physical exercise, reduced circulating levels of trophic factors,
defects in retrograde transport from the nerve ending to the motor neuron soma [28–31], and reduction
in the population of satellite cells around NMJs [32,33].
4. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is an adult-onset, highly debilitating disease that is caused by
the progressive degeneration of upper motor neurons in the motor cortex and of lower motor neurons
in the brainstem and spinal cord. The progressive failure of the neuromuscular system results in
weakness and atrophy of the limb musculature, gradual paralysis, and death from respiratory failure
typically within two to three years of symptom onset [34]. Worldwide ALS incidence is about two
cases/100,000 per year with a prevalence of five cases/100,000. The majority of ALS cases, about
90%, are sporadic (sALS), while about 10% of ALS cases have a family history of the disease and
are classified as familial (fALS) mostly with an autosomal dominant transmission. sALS and fALS
share common clinical symptoms [35]. ALS is known to be a complex disease with a multifactorial
pathogenesis in which several factors could increase the susceptibility to the disease [36], among those
include glutamate-mediated excitotoxicity [37], oxidative stress [38], mitochondrial pool alteration [39]
and dysfunction [35], and abnormal protein aggregation [40].
Possibly viral infections [41,42], autoimmune phenomena [43,44], and several other acquired
causes linked to environmental conditions [45,46] could also contribute to the disease onset.
In 1993, a landmark discovery of 11 missense mutations in the SOD1 gene, in 13 fALS families [47],
heralded the genetic age for ALS. SOD1 is a ubiquitously expressed metallo-protein with a scavenging
effect that functions by detoxifying intracellular superoxide anions. To date, 166 SOD1 mutations have
been reported, accounting for 14–23% familial and 1–7% sporadic ALS cases [48]. It is now known that
mutations in a number of different genes cause fALS and contribute to the development of sALS. In
addition to SOD1 mutations, mutations in the C9orf72 gene, account for 30–40% of fALS in western
countries while, worldwide, TARDBP and FUS gene mutations each account for about 5% of all fALS
cases. Additionally, the best-known ALS-genes, to date more than 100 gene mutations have been
identified, capable of increasing ALS susceptibility or to alter the ALS phenotype in patients. Even if
the origin of motor neuron degeneration remains obscure, multiple mechanisms have been proposed
to contribute to fALS pathogenesis; among these include excitotoxicity, oxidative stress, defects in
protein stability, conformation and aggregation, impairment in cytoskeletal/axonal dynamics, altered
RNA metabolism, mitochondrial dysfunction, and altered neuronal excitability [35].
Int. J. Mol. Sci. 2017, 18, 2092 6 of 16
The possibility to study cellular and molecular processes, identify key pathways for intervention,
and assess multiple candidate therapies over short periods of time, depends on the availability of
animal models for the disease. Forced expression in mice of a human-mutated form of SOD1 (the
mutant SOD1 G93A) resulted in the generation of transgenic mice [49] that recapitulates the pathogenic
phenotype of ALS patients, namely, an adult onset neurodegenerative disease that is characterized by
locomotor impairments, spinal cord and muscular atrophy, motor neuron loss, changes at the NMJ,
muscle denervation, and premature death. Rodents [50], zebrafish [51], but also the fruit fly [52–54]
and the nematode worm [55–57], expressing ALS-linked mutated proteins have been used to study the
neurobiological basis of ALS. Interestingly, those studies based on animal models have shown that
ALS is a non-cell autonomous, multifactorial disease where aberrant behaviors in different cell types,
besides motor neurons, are at play and contribute to the onset and progression of the disease. Among
them, glial cells, which surround motor neurons and provide nutritional and trophic support [58],
TSCs [59], and skeletal muscle fibers [60] could play a crucial role in disease pathogenesis.
5. Neuromuscular Junction Degeneration in Amyotrophic Lateral Sclerosis
Despite numerous studies on motor neuron dysfunction in ALS, it is still debated whether motor
neuron impairment in ALS has to be considered a dying forward phenomenon, in which primary
damages occur in motor neurons in the cortex (i.e., through glutamate excitotoxicity or altered neuronal
excitability) and then extend in an anterograde fashion to corticospinal projections [61], or if ALS
has to be considered a distal axonopathy in which motor neuron degeneration starts at the nerve
endings and progress toward the cell bodies in a dying back manner [62,63]. Given the complexity
of ALS pathogenesis it is reasonable to consider that both dying forward and dying back processes
can occur independently from each other and, regardless of the progression mode, it is acknowledged
that disassembly of the NMJ, leading to skeletal muscle denervation, is a key point in ALS clinical
symptoms onset and pathogenesis.
The notion of ALS as a non-cell autonomous disease is based on the observation that, besides
motor neurons, other cell types are damaged and display altered behavior both in patients and
in vitro/in vivo models of ALS. Moreover, in the past fifteen years, this was shown by expressing
ALS-linked mutant proteins in a tissue or in a cell-specific manner [64].
While it is generally accepted that expression of fALS-linked mutated proteins in motor neurons
is needed to induce an ALS phenotype in mouse models, it is still debated whether this is a sufficient
condition. Initial studies on mice showed that neuron-specific mutant SOD1 expression was not
sufficient for the development of the disease [65,66]. This observation was confirmed by the generation
of chimeric mice where it was shown that, in the absence of mutant SOD1 expression in non-neuronal
cells, mutant SOD1 in neurons was not toxic in itself [67]. On the other hand, a few years later it
was reported that limited expression of mutant SOD1 in neurons was sufficient to induce an ALS
phenotype in mice [68]. The reasons of this difference might be related to different expression levels
of the transgene in the different models. Overall these studies define a scenario in which, in animal
models, the expression of mutant SOD1 in neurons is crucial to determine the onset of the disease and
the early phases of pathogenesis, whereas expression in non-neuronal cells is relevant to modulate
ALS progression.
When analyzing NMJ disassembly in ALS it is necessary to consider the specific role played
by the three components of the tripartite synapse in the series of events that culminate in muscle
fiber denervation.
Despite the wealth of data describing motor neuron degeneration during ALS pathogenesis, quite
a few studies addressed the changes occurring at the motor nerve endings at the NMJ; thus, the series
of events that lead to degeneration of the NMJ circuitry is still poorly understood.
Consistent with the dying-back hypothesis in ALS pathogenesis, it was found that distal axonal
and NMJ alterations were present in muscles of SOD1 G93A mice before the onset of the clinical
symptoms [69]. It was also shown that nerve terminals are particularly sensitive to reactive oxygen
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species (ROS) accumulation and this suggests that oxidative stress, along with altered mitochondria
and increased intracellular Ca2+ levels, accelerates the presynaptic decline in NMJ and affects the
neurotransmitter release machinery in the presynaptic terminals [70]. Ultrastructural analyses of the
presynaptic terminal of NMJs of mutant SOD1 mice at disease onset showed alterations of mitochondria
in terms of cristae disorganization, in a subset of nerve endings, with no differences in average area,
circularity, and density. In agreement with previous reports, these findings indicated that mitochondrial
alterations precede denervation. Synaptic vesicle density in motor axon terminals from mutant SOD1
mice was significantly reduced compared to wild-type ones [39]. The reduction in the size of the
synaptic vesicles pool was previously reported based on immunofluorescence experiments in NMJs of
mutant SOD1 mice, and it was considered as a consequence of impaired vesicle transport in the axons
of fast fatigable motor neurons [71].
Of note, a number of indications about the toxic effects of ALS-linked protein mutations on
the development and maintenance of the nerve endings derived from alternative animal models
(drosophila and Zebrafish ALS models) where the NMJs are more accessible for analyses in vivo and
ex vivo in whole organisms. Indeed, functional and imaging studies have shown that presynaptic
motor nerve terminals’ formation and maturation was impaired at the larval muscle NMJ in drosophila
models of FUS-mediated ALS [72] and that substantial presynaptic defects were observed at the NMJ
in drosophila larvae expressing mutant VAP-B [73].
Expression of mutant SOD1 and reduced expression of TDP-43 in Zebrafish embryos and
larvae both resulted in abnormal motor neuron branching and defective formation of presynaptic
nerve endings [74,75]. Functional data from TDP-43 downregulated embryos also suggested that
reduced levels of this protein cause either increased presynaptic active zones or increased vesicular
quantal release.
6. The Role of Skeletal Muscle in NMJ Dismantling in Amyotrophic Lateral Sclerosis
Little information is available on the role of muscle integrity in preserving fiber innervation in
ALS even if, in mice models of ALS, mutant SOD1 expression in muscle fibers is known to induce a
number of toxic effects that mimic those of mutant SOD1 expression in neurons.
As in neurons, the mitochondrial pool is one of the main intracellular targets of SOD1-mediated
toxicity in the muscle fiber; thus, structural and functional defects were reported in muscle from
sALS patients and transgenic mouse models [60,76], as well as defects in mitochondrial dynamics
that can be observed either at presymptomatic stages [77], or can be undetected and become apparent
with disease progression [78]. Boosting mitochondrial biogenesis with the overexpression of PGC-1α
can restore mitochondrial and muscle functions in SOD1G37R mice without, however, improving
mouse survival [79]. Defects of mitochondrial activity in muscles are accompanied by mutant SOD1
cytosolic aggregates formation which, in muscle, are mostly removed by both proteasome- and
autophagy-mediated degradation [76] and an increased amount of reactive oxygen species.
It has been shown that muscle-specific mSOD1 expression induces progressive muscle
atrophy associated with significant reduction in muscle strength and alterations in the contractile
apparatus [80,81]. Similarly, it was shown that defects in muscle metabolism and the reduction
in muscle mass can be observed in the SOD1 G93A mice before any evidence of central neuron
degeneration [82]. On the contrary, muscle hypertrophy induced by localized expression of insulin-like
growth factor-1 (IGF-1) [83] or growth hormone has been shown to exert beneficial effects on fALS
mouse survival, especially when associated with moderate physical exercise [80,84].
All of these data suggest that skeletal muscle in ALS can be a primary target of the mutant
SOD1 mediated toxicity, however, it is still a matter of debate whether affected muscles play a
role in promoting NMJ denervation and motor neuron degeneration. In fact, while muscle-specific
expression of mutant SOD1 was initially reported to induce a reduction in muscle mass and strength
and mitochondrial dysfunction without effects on motor neuron degeneration [80], later studies
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indicated instead that overexpression of mutant SOD1 only in muscles was able to faithfully reproduce
all major ALS phenotypes, including NMJ alteration and motor neuron degeneration [81].
In support of the idea of a cross talk between motor axon terminals and muscle fibers, it was also
shown that overexpression of Vascular endothelial growth factor (VEGF) and GDNF restricted to the
skeletal muscle of SOD1 G93A significantly delayed the onset of the disease and increased mouse
survival [85,86]. Interestingly VEGF exerted its function in part by counteracting astrogliosis in the
CNS and by preventing NMJs’ denervation in the PNS [87].
Recently it has been shown that the reduced levels and secretion of muscle FGFBP1 at the NMJ
that is observed in aging and in ALS correlates with defects in NMJ stability. Increasing levels of
TGF-β1 in muscle fibers, and specifically at the NMJs, might be at the basis of FGFBP1 decrease [25].
As for NMJ assembly, maintenance and age-related changes, activity might play a role in NMJ
survival in ALS pathogenesis. Recent studies highlighted early defects in cholinergic transmission at
this synapse in ALS patients and models. Whereas neuromuscular transmission of mutant SOD1 mice
was enhanced in the pre-symptomatic phase, it becomes impaired in a subset of NMJs at later stages of
the disease [88]. These defects might be related both to pre- or postsynaptic impairments and, indeed,
studies were performed to analyze the spatiotemporal expression of both the choline acetyltransferase
(ChAT) and vesicular ACh transporter (VAChT) in the motor nerve endings. These two molecules
were both downregulated in tissues from patients and mice models strongly suggesting that reduced
ACh handling in the presynaptic terminals may contribute to motor neuron distal degeneration [89].
Of note, overexpression of VAChT in SOD1 G93A mice slightly increases the level of ACh in the
synaptic cleft of the NMJs, further promoting NMJ degeneration and accelerating disease onset [24].
The integrity of the synaptic basal lamina at the NMJ in ALS has also been investigated, and initial
studies on muscle biopsies from ALS patients have indicated a strong reduction in the levels of
acetylcholine esterase (AChE). This reduction was accompanied by a marked increase in the plasma
level of the circulating enzyme, suggesting a relationship between ALS pathogenesis and protease
activity (matrix metalloproteinases) in the NMJ’s synaptic cleft. This evidence was confirmed by
observations from patients and models of other neuromuscular diseases. However, muscle fibers
are not the only sources of plasma AChE and motor neurons produce and release AChE, whereas
TSCs express on their surface butyrylcholinesterase (BChE); thus, it is difficult to define which of the
partners of the tripartite synapse is mainly responsible for this alteration [89].
Acetylcholine receptors (AChRs) from ALS patients were mostly characterized by the same
pharmacology and the same electrophysiological properties of AChRs from denervated muscles
of non-ALS individuals, however, these receptors showed a significant decrease in ACh affinity,
compared with denervated non-ALS and a four-fold increase in the expression of the α1 subunit
(besides the increase of the γ subunit typical of denervated muscle). Finally, riluzole reduced, in
a dose-dependent manner, ACh-evoked currents. These observations support the hypothesis that
ALS-mediated denervation of skeletal muscle induces changes at the NMJ that are not shared by
denervated muscles after a trauma or because of other neuromuscular pathologies [90,91].
Early studies on muscles from ALS patients showed that the amount and distribution of
acetylcholine receptors, as well as the postsynaptic architecture of the NMJ were not significantly
altered even in fully-denervated endplates [92,93]. In particular it was demonstrated that, whereas the
postsynaptic primary gutter was occasionally flattened (possibly an effect mediated by the reduction
in caliber of denervated fibers), secondary folds were always well preserved [94].
Recent findings in SOD1 G93A mice muscles indicated that, before the onset of clinical symptoms,
NMJs’ increased branching was accompanied by widespread early axonal and NMJ alterations
and immunohistochemical analyses demonstrated that expression levels of the scaffolding proteins
nestin, dystrophin, and rapsyn, as well as those of Lrp4, were diminished at different degrees in the
gastrocnemius. In the same study it was reported that forelimb muscles showed axonal and NMJ
degeneration only later in time, at the post symptomatic stage of the disease and, here, NMJs were
characterized by defects in their morphology and reduced complexity [69].
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All of these data indicate that muscle fibers have to be considered a primary target of ALS-induced
pathogenic events, an important player in ALS initiation and progression, and possibly a target for
therapy. However, and even if they do not unambiguously point to muscle fibers as the synaptic
component primarily triggering NMJ denervation in ALS, they prove that specific defects in muscle
can affect motor nerve ending, thus, contributing to NMJ denervation.
Recent studies on microRNA content in muscle from sporadic and familial ALS patients identified
molecular pathways that could affect re-innervation and muscle fiber regeneration which, subsequently,
could have an impact in maintaining neuromuscular junction stability in ALS [95].
7. Glial Cells, Schwann Cells, and Terminal Schwann Cells in Amyotrophic Lateral
Sclerosis Pathogenesis
In the CNS of animal models expressing mutant SOD1, the role of astrocytes has been extensively
investigated and it was found that, whereas restricted expression of mutant SOD1 in astrocytes was
able to induce astrogliosis, it did not cause motor neuron degeneration [96]. On the other hand,
it was shown that these cells played a relevant role in modulating ALS progression, since delayed
microglial activation and slowed disease progression in SOD1 mice were observed [97,98] by reducing
their level of expression of mutant SOD1. In support of an active role of astrocytes in promoting
motor neuron degeneration in ALS, recent data demonstrated that not only astrocytes expressing
ALS-associated proteins [99], but also astrocytes from sALS patients, are capable of inducing motor
neuron degeneration in vivo [100]. The pathogenic role of mutant SOD1 expression in microglia has
been equally investigated and, also in this case, it was show that by downregulating SOD1 levels in
microglial cells in vivo increased the mean survival of the mutant mice by slowing disease progression
after onset [101,102].
In the peripheral nervous system, the Schwann cells represent the major glial population and can
be divided into two classes: (1) myelinating Schwann cells that ensheath lower motor axons regulating
their caliber and favoring action potential conduction, and (2) non-myelinating terminal Schwann
cells, or perisynaptic Schwann cells, that are needed to support the development, maturation, and
maintenance, as well as the regeneration of the NMJs.
The first evidence of the involvement of Schwann cells in ALS came from observations in autoptic
samples from ALS patients showing myelin sheet disruption in peripheral nerves, most likely the
consequence of axonal degeneration [103]. Later studies in mutant SOD1 mice expressing luciferase
under the control of the Glial Fibrillar Acidic Protein (GFAP) promoter showed that, while in the
spinal cord, astrocyte activation occurred at presymptomatic stages of the disease, the appearance of
the clinical symptoms corresponded with the activation of GFAP expression in myelinating Schwann
cells in the peripheral nervous system (PNS) [104]. Transgenic mice overexpressing mutant SOD1 in
myelinating Schwann cells were generated to investigate whether Schwann cells play a pathogenic role
in the ALS onset and progression by promoting degeneration of NMJs and axons. These animals were
indistinguishable from wild type littermates, suggesting that expression of mutant SOD1 in myelinating
Schwann cells had no effect on motor neurons and was not linked to ALS pathogenesis [105]. Strikingly,
by reducing the expression of a dismutase active mutant SOD1 in myelinating Schwann cells, the
progression of the disease is accelerated [106].
Noteworthy, all the data reported are not applicable as such to non-myelinating TSCs, which are
known to play pivotal roles in NMJs stability and regeneration and, to date, very little is known about
the role of these cells in the pathological changes of the NMJ in ALS.
TSCs play fundamental roles in the physiological re-innervation processes. Upon denervation
TSCs switch from a resting (maintenance) to an active (repair) state and this change is triggered by the
sudden interruption of the ACh signaling through muscarinic AChRs on the TSCs plasma membrane.
TSCs then acquire a macrophage-like behavior and phagocyte axonal and cellular debris; this process
is triggered by mitochondrial factors (alarmins) [107] that are released by degenerating axons, and is
relevant to promote and facilitate re-innervation. Given the tight relationship between mutant SOD1
Int. J. Mol. Sci. 2017, 18, 2092 10 of 16
toxicity and mitochondrial alterations in neurons [108], these data suggest that debris phagocytosis by
TSCs in ALS might be impaired affecting efficient reinnervation processes [109].
Activated TSCs are equally important for the guidance of axonal sprouting to reinnervate the
previously-occupied synaptic clefts, to remodel the post-synaptic clusters of AChRs, and to stabilize
newly-reinnervated NMJs [110]. These functions, which are mostly mediated by the extension of TSC
processes, are phenomena that do not seem to be impaired in ALS mouse models [111]. Interestingly,
TSCs switching from maintenance to repair at the NMJ could be dampened instead by an impaired
muscarinic activation of the TSCs. In support of this hypothesis is evidence of hyper-muscarinic
activity of TSCs in mutant SOD1 mice at disease onset [111]. Thus, persistent muscarinic activation of
TSCs might be one of the causes of defects in the NMJ architecture and function in ALS progression.
Deregulated Ca2+ homeostasis in glial cells was equally reported as a consequence of
over-activation both in astrocytes in the CNS [112] and in TSCs at the NMJs [111]. Given the number
and the relevance of the intracellular pathways that are activated/regulated by cytoplasmic calcium
concentration it is conceivable that glial over-activation might result in mitochondrial overload,
enhanced free radical production, ER, and oxidative stress [59].
Recent data from mutant SOD1 mice have shown that TSCs undergo morphological alteration
and reduction in their number before NMJ denervation [113], and many of them further react to
denervation by activating their apoptotic pathways instead of promoting reinnervation [114], thus, any
motor neuron sprouting from nearby innervated NMJ is unlikely to provide successful compensatory
reinnervation in muscles from these mice. On the other hand, reduction in the total number of TSCs
might result in alteration of the signaling pathways that are important for NMJ repair and proper
function, as, for example, the neuregulin-ErbB pathway. Neuregulin (NRG) and its receptors (ErbBs)
are present at adult NMJ with ErbB3 specifically localized at TSCs’ plasma membrane. Evidence from
several experiments indicated that the integrity of the NRG-ErbB signaling pathway in TSCs was
crucial to maintaining the stability of the NMJ as both its over-activation in ALS and downregulation
resulted in synaptic loss [59]. NRG expression is reduced in the spinal cord of ALS patients and mice
models and viral mediated delivery on NRG1 in mice could extend mice survival [115]. Disruption
of the neuregulin-ErbB4 pathway, induced by the loss of function mutation in the ErbB4 gene, was
equally involved in the pathogenesis of ALS [116].
8. Conclusions
The assembly, maintenance, and plasticity of neuromuscular junctions are differentially regulated
by numerous signaling pathways activated by the cross-talk among the three partners of the NMJ
(motor nerve ending, muscle fiber, and terminal Schwann cell) in development (embryonic and early
postnatal life), adulthood, and during aging. Interestingly, several of the neuromuscular signaling
impairments that lead to age-related changes at the NMJ occur in pathological conditions in which
NMJ disassembly and skeletal muscle denervation are key events, like in ALS.
For many years, in the ALS community, researchers tried to identify the cellular component(s)
that were primarily responsible for NMJ disassembly in ALS, moving rapidly from the concept of a
cell-autonomous to a non-cell-autonomous mechanism, where all three members of this peripheral
tripartite synapse play specific roles in ALS onset and progression.
As for NMJ assembly during development, it is now clear that neurocentric or myocentric
hypotheses for NMJ dismantling are too tight in their definition and that the trigger for NMJ
disassembly in ALS is possibly represented by the cross-talk not only between muscle fiber and
motor nerve terminals, but also, as it has clearly emerged in the last few years, in the cross-talk of these
two elements with the terminal Schwann cells.
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